Mixed Salts Of A Single Entity Amphetamine Product Xr while Breastfeeding

What is Mixed Salts Of A Single Entity Amphetamine Product Xr used for?

Is Mixed Salts Of A Single Entity Amphetamine Product Xr safe to use while breastfeeding? Can it interfere with growth and development of my kid?

Dextroamphetamine sulfate while Breastfeeding

CAS Number: 51-63-8

A sympathomimetic drug and central nervous system stimulant, it has a similar action and uses to amphetamine, its dextro isomer.It is used (GSK, 2007) in the treatment of narcolepsy (Wise, 2007) and Attention Deficit Hyperactivity Disorder (ADHD), and is also used as an illegal drug (Oei, 2012). It is excreted in breast milk, concentrating about 3 times more than in plasma. This concentration assumes a relative dose about 6% (Ilett, 2007). In infants whose mothers were taking dexamfetamine as treatment for ADHD, levels ranging from undetectable to 14% of maternal plasma levels have been measured and no problems were observed in the clinical follow-up of these infants (Ilett, 2007). There is little information on the impact of amphetamine abuse on the development and health of infants (Oei, 2012, Wise, 2007; Moretti, 2000), but it is known that they are more exposed to social problems, domestic violence, and lower breastfeeding rates (Oei, 2010). There is controversy over the possibly mild negative effect of amphetamine on prolactin (Petraglia, 1987; DeLeo, 1983), but milk production in mothers who took it therapeutically was not affected (Öhman, 2015). During breastfeeding, the therapeutic use (narcolepsy, ADHD) of dexamphetamine can be assessed, using the lowest possible effective dose and monitoring the occurrence of irritability, insomnia, lack of appetite and weight loss. Its use as an illegal drug is totally discouraged (Oei, 2012). See below the information of these related products:

Dextroamphetamine saccharate while Breastfeeding

CAS Number: 51-63-8

A sympathomimetic drug and central nervous system stimulant, it has a similar action and uses to amphetamine, its dextro isomer.It is used (GSK, 2007) in the treatment of narcolepsy (Wise, 2007) and Attention Deficit Hyperactivity Disorder (ADHD), and is also used as an illegal drug (Oei, 2012). It is excreted in breast milk, concentrating about 3 times more than in plasma. This concentration assumes a relative dose about 6% (Ilett, 2007). In infants whose mothers were taking dexamfetamine as treatment for ADHD, levels ranging from undetectable to 14% of maternal plasma levels have been measured and no problems were observed in the clinical follow-up of these infants (Ilett, 2007). There is little information on the impact of amphetamine abuse on the development and health of infants (Oei, 2012, Wise, 2007; Moretti, 2000), but it is known that they are more exposed to social problems, domestic violence, and lower breastfeeding rates (Oei, 2010). There is controversy over the possibly mild negative effect of amphetamine on prolactin (Petraglia, 1987; DeLeo, 1983), but milk production in mothers who took it therapeutically was not affected (Öhman, 2015). During breastfeeding, the therapeutic use (narcolepsy, ADHD) of dexamphetamine can be assessed, using the lowest possible effective dose and monitoring the occurrence of irritability, insomnia, lack of appetite and weight loss. Its use as an illegal drug is totally discouraged (Oei, 2012). See below the information of these related products:

Amphetamine aspartate monohydrate while Breastfeeding

CAS Number: 300-62-9

A sympathomimetic drug and central nervous system stimulant, it has a similar action and uses to its isomer dextroamphetamine.It is used in the treatment of narcolepsy (Wise, 2007) and Attention Deficit Hyperactivity Disorder (ADHD), and is also used as an illegal drug (Oei, 2012; Bartu, 2009). It is excreted in breast milk, concentrating between 2 and 8 times more than in plasma (FDA, 2017; Steiner, 1984). This concentration, although it could be significant (Bartu, 2009), assumes a relative dose between 2% (Öhman, 2015) and 13.8% (FDA, 2017). In infants whose mothers were taking amphetamine as narcolepsy treatment, low plasma levels (Öhman, 2015) and urine (Steiner, 1984) were measured and no problems were observed in the clinical follow-up of these infants (Öhman, 2015; Steiner, 1984). There is little information on the impact of amphetamine abuse on the development and health of infants (Oei, 2012, Wise, 2007; Moretti, 2000), but it is known that they are more exposed to social problems, domestic violence, and lower breastfeeding rates (Oei, 2010). To minimize the risk, it is estimated that 48 hours should pass after the last amphetamine-based recreational use, before breast-feeding (Bartu, 2009). There is controversy over the possibly mild negative effect of amphetamine on prolactin (Petraglia, 1987; DeLeo, 1983), but milk production in mothers who took it therapeutically was not affected (Öhman, 2015). During breastfeeding, the therapeutic use (narcolepsy, ADHD) of amphetamine can be assessed, using the lowest possible effective dose and monitoring the occurrence of irritability, insomnia, lack of appetite and weight loss. Its use as an illegal drug is totally discouraged (Oei, 2012).

Amphetamine sulfate while Breastfeeding

CAS Number: 300-62-9

A sympathomimetic drug and central nervous system stimulant, it has a similar action and uses to its isomer dextroamphetamine.It is used in the treatment of narcolepsy (Wise, 2007) and Attention Deficit Hyperactivity Disorder (ADHD), and is also used as an illegal drug (Oei, 2012; Bartu, 2009). It is excreted in breast milk, concentrating between 2 and 8 times more than in plasma (FDA, 2017; Steiner, 1984). This concentration, although it could be significant (Bartu, 2009), assumes a relative dose between 2% (Öhman, 2015) and 13.8% (FDA, 2017). In infants whose mothers were taking amphetamine as narcolepsy treatment, low plasma levels (Öhman, 2015) and urine (Steiner, 1984) were measured and no problems were observed in the clinical follow-up of these infants (Öhman, 2015; Steiner, 1984). There is little information on the impact of amphetamine abuse on the development and health of infants (Oei, 2012, Wise, 2007; Moretti, 2000), but it is known that they are more exposed to social problems, domestic violence, and lower breastfeeding rates (Oei, 2010). To minimize the risk, it is estimated that 48 hours should pass after the last amphetamine-based recreational use, before breast-feeding (Bartu, 2009). There is controversy over the possibly mild negative effect of amphetamine on prolactin (Petraglia, 1987; DeLeo, 1983), but milk production in mothers who took it therapeutically was not affected (Öhman, 2015). During breastfeeding, the therapeutic use (narcolepsy, ADHD) of amphetamine can be assessed, using the lowest possible effective dose and monitoring the occurrence of irritability, insomnia, lack of appetite and weight loss. Its use as an illegal drug is totally discouraged (Oei, 2012).

Dextroamphetamine sulfate while Breastfeeding

CAS Number: 51-64-9

In dosages prescribed for medical indications, some evidence indicates that dextroamphetamine might not affect nursing infants adversely. The effect of dextroamphetamine in milk on the neurological development of the infant has not been well studied. It is possible that large dosages of dextroamphetamine might interfere with milk production, especially in women whose lactation is not well established. Relevant published information was not found as of the revision date on the safety of breastfeeding during amphetamine abuse. One expert recommends that amphetamines not be used therapeutically in nursing mothers.[1]

Dextroamphetamine saccharate while Breastfeeding

CAS Number: 51-64-9

In dosages prescribed for medical indications, some evidence indicates that dextroamphetamine might not affect nursing infants adversely. The effect of dextroamphetamine in milk on the neurological development of the infant has not been well studied. It is possible that large dosages of dextroamphetamine might interfere with milk production, especially in women whose lactation is not well established. Relevant published information was not found as of the revision date on the safety of breastfeeding during amphetamine abuse. One expert recommends that amphetamines not be used therapeutically in nursing mothers.[1]

Amphetamine aspartate monohydrate while Breastfeeding

CAS Number: 300-62-9

In dosages prescribed for medical indications, some evidence indicates that amphetamine does not affect nursing infants adversely. The effect of amphetamine in milk on the neurological development of the infant has not been well studied. Large dosages of amphetamine might interfere with milk production, especially in women whose lactation is not well established. Breastfeeding is generally discouraged in mothers who are actively abusing amphetamines.[1][2][3] One expert recommends that amphetamine not be used therapeutically in nursing mothers.[4]

Amphetamine sulfate while Breastfeeding

CAS Number: 300-62-9

In dosages prescribed for medical indications, some evidence indicates that amphetamine does not affect nursing infants adversely. The effect of amphetamine in milk on the neurological development of the infant has not been well studied. Large dosages of amphetamine might interfere with milk production, especially in women whose lactation is not well established. Breastfeeding is generally discouraged in mothers who are actively abusing amphetamines.[1][2][3] One expert recommends that amphetamine not be used therapeutically in nursing mothers.[4]

I am nursing mother and I have already used Mixed Salts Of A Single Entity Amphetamine Product Xr, what should I do?

My health care provider has asked me to use Mixed Salts Of A Single Entity Amphetamine Product Xr, what to do?

If I am using Mixed Salts Of A Single Entity Amphetamine Product Xr, will my baby need extra monitoring?

Who can I talk to if I have questions about usage of Mixed Salts Of A Single Entity Amphetamine Product Xr in breastfeeding?